SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): March 27, 2008
000-51379
(Commission
File Number)
______________________________
CHINA
MEDICINE CORPORATION
(Exact
name of registrant as specified in its charter)
|
Delaware
|
51-0539830
|
|
(State
of Incorporation)
|
(IRS
Employer
|
|
|
Identification
No.)
|
Guangri
Tower, Suite 702
No.
8
Siyou South 1st Street
Yuexiu
District
Guangzhou,
China 510600
(Address
of registrant’s principal executive office)
(8620)
8739-1718 and (8620) 8737-8212
(Registrant’s
telephone number)
Check
the
appropriate box below in the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
£
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
£
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.
14a-12)
£
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
£
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other
Events.
On
March
27, 2008, China Medicine Corporation (the “Company”) issued a press release
announcing financial results for the quarter and year ended December 31,
2007. A
copy of the Company’s press release is attached hereto as Exhibit
99.1.
Item
9.01 Financial
Statements and Exhibits.
(d) Exhibits
|
Exhibit
No.
|
Description
|
|
|
|
|
99.1
|
Press
Release, dated March 27,
2008
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
CHINA
MEDICINE CORPORATION
By: /s/ Senshan
Yang
Name:
Senshan Yang
Title: Chief
Executive Officer
Date: March
27, 2008